FDA nod to Tibotec’s PREZISTA for treating HIV-1 infection
The U.S. Food and Drug Administration has expanded the indication for Tibotec Pharmaceuticals’ PREZISTA (darunavir) tablets once-daily dosing as a part of the HIV combination therapy in adult patients who have not taken medication for HIV before. Also, PREZISTA has been approved as a twice-daily for use in adults with a prior experience of treatment. With this approval, the protease inhibitor when administered with 100 mg PREZISTA/r (ritonavir) and other ARVs (antiretroviral agents) can be used for the treatment of HIV-1 infection.
- FDA approves Reyataz capsules for treating HIV-1 infection
- Novartis vaccine shows stronger immune response against meningococcal strains
- Inverness Medical launches Determine HIV-1/2 Ag/Ab Combo test for HIV diagnosis
- Anti-inflammatory drugs might treat resistant cancer
